September 16th 2024
Your daily dose of the clinical news you may have missed.
September 11th 2024
EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.
September 10th 2024
September 9th 2024
Once-daily oral TERNS-601 was associated with a significant mean 5% weight reduction after 28 days and had a favorable tolerability profile.
Prevalence of Type 1 and Type 2 Diabetes “Surging” among US Youth, Shows New Study
From 2001 to 2017, the estimated prevalence of youth-onset T1D and T2D increased approximately 45% and 95%, respectively, according to a new study.
High-deductible Health Plans May Negatively Impact Patients with Diabetes, New Review Suggests
Low-income patients with diabetes enrolled in high-deductible health plans used less preventive and primary care services and more emergency visits, suggests new review.
8 Questions on Diabetes Drugs for Cardioprotection
Take this quick quiz to test your knowledge of key findings in landmark studies on the cardioprotective effects of SGLT2i and GLP-1 RAs.
Diabetes Drugs and Cardioprotection: A Summary for Primary Care
These concise summaries highlight the latest findings on the cardioprotective effects of SGLT2 inhibitors and GLP-1 RA in patients with diabetes.
In Patients with Uncontrolled T2D, Bariatric Surgery Associated with Long-term Improvement in Physical Domains, Diabetes-related QoL
Five years after bariatric surgery for uncontrolled T2D patients reported improvements in physical health and QoL but measures of psychosocial wellbeing remained flat.
Achieving A1c Levels Below 7% Early May be Predictive of Long-term Glycemic Control in Patients with T2D
Early attainment of an A1c level below 7% was predictive of long-term glycemic control in patients with type 2 diabetes starting second-line glucose-lowering therapy in a new analysis.
Study: Statins Reduce CVD, Mortality in Low-risk Patients with Type 2 Diabetes
A recent study found that the use of statins in patients with newly diagnosed T2D reduced incidence of cardiovascular disease and death, particularly among older patients.
ADA 2021: Baseline Insulin Use May not Impact Benefits of Finerenone in Patients with CKD, T2D
ADA 2021. A subgroup analysis of the FIDELIO-DKD trial showed that finerenone use was beneficial regardless of baseline insulin use among patients with T2D and CKD.
ADA 2021: Use of Dapagliflozin Decreases Risk of Diabetes in Patients with CKD
ADA 2021. Dapagliflozin was found to reduce type 2 diabetes incidence among patients with chronic kidney disease in a prespecified analysis of the DAPA-CKD trial.
ADA 2021: Study Finds Hospitalization Rates for New-onset Pediatric T2D Doubled During Pandemic
Data released today at the American Diabetes Association 81st Scientific Sessions on a spike in new onset pediatric T2D at a single center during COVID-19 may signal much wider incidence.
ADA Virtual Meeting Will Offer 5 Symposia on Latest COVID-19 Findings
The upcoming ADA virtual 81st Scientific Sessions will feature 5 sessions on the latest diabetes developments learned during the initial phases of the COVID-19 pandemic.
Novel “Smart” Pen Cap for Insulin Dosing Receives FDA Clearance in Patients with Diabetes
The novel Bigfoot Unity Diabetes Management System could help improve insulin dosing in patients with type 1 or type 2 diabetes.
8 Questions on T2 Diabetes Risk Assessment Using Prediabetes Subphenotypes
Assessment of prediabetes subphenotypes is a novel approach to better screening, prevention, and treatment for patients at risk of progression to T2D. Find out how much you know about it.
CGM Improves Glycemic Control in Patients with T2D on Basal Insulin Alone
MOBILE study group: in patients with type 2 diabetes on a less intensive insulin regimen, CGM use lowered A1c and increased time in target glucose range vs traditional blood glucose monitoring.
Bariatric Surgery Associated with Reduced Mortality in Patient with T2D, Obesity
Authors of a new study say their findings suggest bariatric surgery should be considered first-line treatment for the management of obesity in patients with type 2 diabetes.
Study: GLP-1 Receptor Agonist Therapy Reduces Asthma Exacerbations in Adults with Asthma, T2D
New findings suggest that patients with asthma and type 2 diabetes who use GLP-1 RAs for diabetes treatment intensification have fewer asthma exacerbations compared to other diabetes drugs.
Lifestyle Counseling in Primary Care Setting May Reduce Incidence of T2D in High-risk Patients
A recent study showed lifestyle counseling in primary care was effective in preventing type 2 diabetes in long-term follow-up.
Diabetes in Patients with CAD Independently Associated with Mortality, CV Events
In individuals with chronic coronary disease, the presence of diabetes increased the rate of death by 38% during a 5-year follow-up period in analysis of a worldwide patient registry.
Study: Black Women with PCOS Have Greater Cardiometabolic Risk vs White Women
ENDO 2021: A meta-analysis found increased cardiometabolic risk among Black women with PCOS vs White counterparts even though fasting glucose levels were comparable and triglyceride levels lower.
Study: Lifestyle Program Improves Fertility in Women with Obesity and Infertility
A lifestyle intervention targeting women with obesity and infertility is more effective in increasing the pregnancy rate vs fertility treatments, suggests a new study presented at ENDO 2021.
Hyperglycemia in Hospitalized COVID-19 Patients Linked with Worse Outcomes
COVID-19 patients with hyperglycemia on hospital admission, with and without diabetes, had increased odds of intubation, ICU admission, and mortality, according to research presented at ENDO 2021.
Novel Once-weekly Insulin as Effective as Once-daily in Type 2 Diabetes with Less Hypoglycemia, Weight Gain
ENDO 2021: An investigational once-weekly insulin formulation was found as effective as daily basal insulin injection for glucose control with lower rates of hypoglycemia and less weight gain.
Chronic Diseases in Multimorbidity May Share Origins, Study Finds
Using metabolomic profiling from more than 11 000 individuals, researchers identified common pathways linking seemingly unrelated diseases that often co-occur.
Eli Lilly’s Tirzepatide Significantly Reduced A1c, Body Weight in Adults with T2D
Results from a head-to-head study show the investigational medication, tirzepatide, led to superior A1c and body weight reductions compared to semaglutide.
Semaglutide Associated with Substantial Weight Loss in Patients with Obesity
More than half of adults with obesity who received once-weekly semaglutide lost 15% of body weight, according to the recently published STEP 1 study.
Use of CGM during Early Weeks of COVID-19 Found to Improve Time in Range
A new review of >60 000 patients with diabetes found CGM use during the early weeks of the COVID-19 pandemic improved their time in range.
Obesity Linked to Over Half of New Type 2 Diabetes Cases in US Annually
New research suggests obesity is responsible for 30%-53% of new type 2 diabetes cases in the US annually.
Study: Metabolic Surgery May be Cure for Type 2 Diabetes
Compared to medication and lifestyle changes, metabolic surgery is more effective in the long-term control of severe T2D, a new study found.
Sotagliflozin: CV Benefit Seen in Patients with T2 Diabetes, Worsening Heart Failure
Sotagliflozin reduced CV death and hospitalization for HF in patients with T2D and acute symptomatic HF when given during or immediately after hospitalization.
Professor John McMurray Highlights DAPA-CKD Trial Outcomes
DAPA-CKD investigator Professor John McMurray details the trial and renal and cardiovascular outcomes for Patient Care Online.